A long-term follow-up study of cerebrospinal fluid acetylcholinesterase in delirium

Cerebrospinal fluid acetylcholinesterase (CSF AChE) was determined for elderly delirious patients during the acute stage and after a 1- and 4-year follow-up periods, and the AChE levels were compared with age-equivalent controls. The AChE levels measured during the index admission correlated with th...

Full description

Saved in:
Bibliographic Details
Published in:European archives of psychiatry and clinical neuroscience 1994-11, Vol.243 (6), p.347-351
Main Authors: KOPONEN, H. J, SIRVIÖ, J, LEPOLA, U, LEINONEN, E, RIEKKINEN, P. J
Format: Article
Language:English
Subjects:
Acetylcholinesterase - cerebrospinal fluid
Adult and adolescent clinical studies
Aged
Aged, 80 and over
Biological and medical sciences
Brain Damage, Chronic - enzymology
Brain Damage, Chronic - mortality
Delirium - enzymology
Delirium - mortality
Female
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Organic mental disorders. Neuropsychology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cerebrospinal fluid acetylcholinesterase (CSF AChE) was determined for elderly delirious patients during the acute stage and after a 1- and 4-year follow-up periods, and the AChE levels were compared with age-equivalent controls. The AChE levels measured during the index admission correlated with the length of life after delirium, suggesting that cholinergic dysfunction may have prognostic significance in delirious patients. Although the CSF AChE concentrations measured during the index admission were in the same range as in controls, we observed a declining trend in patients with various structural brain diseases during the follow-up period. The decreasing levels may reflect the progression of the underlying dementia in these patients.
ISSN:0940-1334
1433-8491
DOI:10.1007/BF02195729